$NNOX

Meltzer Erez purchased $7K of NNOX (indirect holdings)

Meltzer Erez (Chief Executive Officer) purchased 10,000 indirectly-held shares of Nano-X Imaging Ltd. (NNOX) at $0.69 on 2026-09-15.

Original reporting
SEC EDGAR · Meltzer Erez
Published Sep 16, 2026, 10:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NNOX
Bullish
medium confidence
Mentioned
$NNOX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NNOXBullishLow
01

Why it matters

The transaction is a primary disclosure but materiality is low due to small dollar amount.

02

Market read

Insider purchase is modest; unlikely to move the stock significantly.

03

What to watch

Potential upcoming financing or dilution events that could offset the insider's stake.

Relevance 3/10Novelty 4/10Timing: post‑market filing on Sep 16, 2026

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$NNOXBullishMedium confidence
Context

CEO Meltzer Erez purchased 10,000 shares for $6,900, increasing his stake to 65,443 shares.

Expected impact

Minimal upside, likely negligible price movement.

Evidence & confidence

The purchase size is tiny relative to market cap; any impact will be limited.

Market effects

None significant for the medical imaging sector.

No regional effect; limited to Nano‑X shareholders.

Minimal global relevance.

Counterpoint

The buy could be a routine portfolio adjustment rather than a confidence signal.

Key entities

  • Meltzer Erez

    Chief Executive Officer of Nano‑X Imaging Ltd.

  • Nano‑X Imaging Ltd.

    Medical imaging company listed on Nasdaq under NNOX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NNOXMed

Nano X Imaging Ltd (NNOX) (Q2 2026) Earnings Call Highlights: Re

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

$NNOXHigh

Nano-X Imaging Ltd. (NNOX): Financial results for Q2 2026

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

$NNOXMed

NANO-X IMAGING LTD: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.